Boston Scientific Corporation (N:BSX)

Business Focus: Advanced Medical Equipment & Technology

Apr 08, 2024 12:00 am ET
Boston Scientific Initiates NAVIGATE-PF Study of the FARAWAVE™ Nav Pulsed Field Ablation Catheter and FARAVIEW™ Software Module
MARLBOROUGH, Mass., April 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize and track the FARAWAVE™ Nav Pulsed Field Ablation (PFA) Catheter* for the treatment of patients with paroxysmal and persistent atrial fibrillation (AF). The FARAVIEW technology and the FARAWAVE Nav catheter expand the capabilities of the FARAPULSE™ PFA System through integration with our cardiac mapping system.
Apr 01, 2024 08:00 am ET
Boston Scientific Announces Conference Call Discussing First Quarter 2024 Results
MARLBOROUGH, Mass., April 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2024, on Wednesday, April 24, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 24 prior to the conference call.
Feb 22, 2024 08:27 pm ET
Boston Scientific Announces Pricing of €2.0 Billion of Senior Notes
MARLBOROUGH, Mass., Feb. 22, 2024 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has priced a public offering of €750,000,000 aggregate principal amount of 3.375% notes due 2029 and €1,250,000,000 aggregate principal amount of 3.500% notes due 2032 (collectively, the "Notes"). The Notes will be fully and unconditionally guaranteed by the Company. The offering is being made pursuant to a registration statement filed with the U.S. Securities and Exchange Commission. 
Feb 20, 2024 03:00 am ET
Medical Technology Stocks to Keep On The Radar
The healthcare technology industry is one that offers investors a plethora of opportunities. With global healthcare spending soaring to approximately $8.3 trillion and nearly half of that amount allocated in the U.S. alone, the sector presents intriguing growth prospects. As the healthcare industry outpaces the overall global economy in growth, investors find themselves on the cusp of a promising market.
Feb 14, 2024 08:15 am ET
Boston Scientific: Meeting Disabilities With Inclusion
NORTHAMPTON, MA / ACCESSWIRE / February 14, 2024 / Boston Scientific
Feb 07, 2024 08:45 am ET
Boston Scientific: Honoring Our Indigenous Community - Past, Present and Future
NORTHAMPTON, MA / ACCESSWIRE / February 7, 2024 / For more than 30 years, November has been celebrated as Native American Heritage Month (formerly National American Indian Heritage Month) in the United States. It's a time to recognize the long, rich history of the country's many Indigenous peoples - and to acknowledge the unique challenges they have faced and continue to face.
Feb 05, 2024 07:00 am ET
Boston Scientific to Participate in TD Cowen's 44th Annual Health Care Conference
MARLBOROUGH, Mass., Feb. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 44th Annual Health Care Conference on Wednesday, March 6, 2024.
Feb 02, 2024 08:15 am ET
Boston Scientific: Sparking Social Change Through Volunteering
NORTHAMPTON, MA / ACCESSWIRE / February 2, 2024 / Imagine being offered the chance to spend a week in another country meeting new people and helping a nonprofit health care organization - all as part of your day job.
Jan 31, 2024 05:30 am ET
Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $504 million or $0.34 per share (EPS), compared to $126 million or $0.09 per share a year ago and achieved adjusted3 EPS of $0.55 for the period, compared to $0.45 a year ago.
Jan 31, 2024 05:25 am ET
Boston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System
Strong clinical evidence base, largest volume of real-world use reinforce safety, efficacy and efficiency advantages of the system
Jan 26, 2024 10:18 pm ET
AXONICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
NEW ORLEANS, Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of  Axonics, Inc. (NasdaqGS: AXNX) to Boston Scientific Corporation (NYSE: BSX).  Under the terms of the proposed transaction, shareholders of Axonics will receive $71.00 in cash for each share of Axonics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Jan 22, 2024 03:00 am ET
Top 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX)
Investors eyeing dynamic opportunities in healthcare should take note of the burgeoning growth anticipated in the spinal cord injury market. Projections for robust advancements, driven by enhanced diagnosis and increased global healthcare spending, signal a lucrative trajectory from 2023 to 2032, with a significantly positive CAGR, according to Delveinsights.
Jan 16, 2024 08:05 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AX
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jan 08, 2024 05:31 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AX
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jan 08, 2024 03:55 pm ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Axonics, Inc.
NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Axonics, Inc. (NASDAQ: AXNX) and its board of directors concerning the proposed acquisition of the company by Boston Scientific Corporation (NYSE: BSX). Stockholders will receive $71.00 for each share of Axonics stock that they hold. The transaction is valued at approximately $3.7 billion and is expected to close in the first half of 2024.
Jan 08, 2024 07:00 am ET
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific
Axonics, Inc. (Nasdaq: AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion.
Jan 08, 2024 06:00 am ET
Boston Scientific Announces Agreement to Acquire Axonics, Inc.
Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction
Jan 05, 2024 07:00 am ET
Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results
MARLBOROUGH, Mass., Jan. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2023, on Wednesday, January 31, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the fourth quarter on January 31 prior to the conference call.
Dec 28, 2023 03:00 pm ET
Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation
MARLBOROUGH, Mass., Dec. 28, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) System* as a first-line treatment for persistent atrial fibrillation (AF), the only trial to study the use of PFA as frontline therapy in patients with this form of AF. Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AA
Dec 12, 2023 08:15 am ET
Boston Scientific: When a Loved One Has Parkinson’s Disease
NORTHAMPTON, MA / ACCESSWIRE / December 12, 2023 / Boston Scientific
Dec 05, 2023 09:45 am ET
Meet Three Boston Scientific Employees Committed to Protecting People From Stroke
NORTHAMPTON, MA / ACCESSWIRE / December 5, 2023 / Advancing science for life is at the core of all we do at Boston Scientific. Our products treat and prevent a broad range of conditions that can diminish a person's quality of life, including stroke. Affecting more than 12 million people annually, stroke happens when blood flow to the brain is reduced or blocked, a
Nov 27, 2023 10:15 am ET
Boston Scientific Costa Rica Facility Awarded Gender Equality Seal
NORTHAMPTON, MA / ACCESSWIRE / November 27, 2023 / Our Costa Rica Manufacturing Sites and Commercial Office were awarded the Gender Equality Seal from INAMU (Instituto Nacional de las Mujeres/National Women's Institute). Congratulations to our team in Costa Rica and thank you for your important work toward advancing gender equality.
Nov 17, 2023 08:00 am ET
Boston Scientific Closes Acquisition of Relievant Medsystems, Inc.
Recent healthcare plan coverage of Intracept® system expands access to vertebrogenic pain treatment for tens of millions of patients
Nov 14, 2023 09:15 am ET
To Keep Patients Safe and Their Data Secure, We Need To Work Together
by Drew Bomett, VP & Chief Information Security Officer, Boston Scientific
Nov 07, 2023 09:15 am ET
Boston Scientific's Sandra Nagale Predicts the Future of Medtech Powered by AI Innovations
NORTHAMPTON, MA / ACCESSWIRE / November 7, 2023 / Boston ScientificOriginally published by DeviceTalks
Nov 01, 2023 08:00 am ET
Boston Scientific to Participate in Stifel's 2023 Healthcare Conference
MARLBOROUGH, Mass., Nov. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Stifel's 2023 Healthcare Conference on Tuesday, November 14, 2023.
Oct 31, 2023 09:15 am ET
"I Love Boston Scientific So Much, It Is Now in My Heart"
NORTHAMPTON, MA / ACCESSWIRE / October 31, 2023 / Boston Scientific / Cynthia doesn't even want to think about what could've happened if she didn't go in for that check-up.
Oct 26, 2023 06:30 am ET
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2023
MARLBOROUGH, Mass., Oct. 26, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported basis, 11.1 percent on an operational1 basis and 10.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $505 million or $0.34 per share (EPS), compared to $174 million or $0.12 per share a year ago, and achieved adjusted3 EPS of $0.50 for the period, compared to $0.43 a year ago.
Oct 25, 2023 02:29 pm ET
Boston Scientific AGENT™ Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial
Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB
Oct 24, 2023 03:18 pm ET
REAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of Pulmonary Embolism
Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices
Oct 24, 2023 08:15 am ET
Boston Scientific: What Is Ideal Product Flow, and How Does It Help Healthcare Providers, Patients and the Planet?
NORTHAMPTON, MA / ACCESSWIRE / October 24, 2023 / Boston ScientificBy Paudie O'Connor SVP, Global Supply Chain
Oct 17, 2023 08:15 am ET
Boston Scientific: Bridging Cultural and Language Barriers at Work Through Mentoring
NORTHAMPTON, MA / ACCESSWIRE / October 17, 2023 / Ilonkis Lum first joined the Hispanic Organization for Leadership & Achievement (HOLA) employee resource group (ERG) to meet people outside of her team at Boston Scientific, where she's a Senior Product Owner in the Product Information Management group. But Lum has gotten more than that out of her membership: She's also learning how to communicate better with her colleagues, making her a stronger performer at work.
Oct 02, 2023 06:30 am ET
Boston Scientific Announces Conference Call Discussing Third Quarter 2023 Results
MARLBOROUGH, Mass., Oct. 2, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ending September 30, 2023, on Thursday, October 26, 2023, at 8:00 a.m. EDT. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter on October 26 prior to the conference call.
Sep 27, 2023 08:15 am ET
Boston Scientific: Encouraging and Empowering Tomorrow’s STEM Pioneers
NORTHAMPTON, MA / ACCESSWIRE / September 27, 2023 / At Boston Scientific, we strive to advance science for life, which includes inspiring the next generation of STEM professionals who will help shape the future of health care. Using a combination of hands-on experiences and classroom education, our employee STEM councils helped more than 70,000 young people explore careers in Science, Technology, Engineering and Math in 2022.
Sep 21, 2023 08:15 am ET
What Is the Boston Scientific Foundation?
NORTHAMPTON, MA / ACCESSWIRE / September 21, 2023 / Boston Scientific
Sep 21, 2023 06:45 am ET
CVS Health appoints Michael F. Mahoney to its Board of Directors
WOONSOCKET, R.I., Sept. 21, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) has appointed Michael F. Mahoney, Chairman and CEO of Boston Scientific Corporation (NYSE: BSX), a global medical technology leader, to serve on the Board of Directors (the "Board") of CVS Health, effective November 1.
Sep 19, 2023 07:00 am ET
Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.
Acquisition intended to expand neuromodulation portfolio to provide more treatment options for people living with chronic low back pain
Aug 03, 2023 08:00 am ET
Building Disability Inclusion
NORTHAMPTON, MA / ACCESSWIRE / August 3, 2023 / Boston Scientific
Jul 31, 2023 09:00 am ET
Privia Health Announces Changes to Board of Directors
Privia Health Group, Inc. (Nasdaq: PRVA) today announced the election of David S. Wichmann and Pamela O. Kimmet to its Board of Directors, effective August 1, 2023. Jeff Bernstein, Managing Director of Goldman Sachs, will resign from the Board...
Jul 27, 2023 06:34 am ET
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR SECOND QUARTER 2023
MARLBOROUGH, Mass., July 27, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.599 billion during the second quarter of 2023, growing 11.0 percent on a reported basis, 12.0 percent on an operational1 basis and 11.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $261 million or $0.18 per share (EPS), compared to $246 million or $0.17 per share a year ago, and achieved adjusted3 EPS of $0.53 for the period, compared to $0.44 a year ago.
Jul 19, 2023 08:00 am ET
Meet Three Boston Scientific Employees on a Mission To Give Back
NORTHAMPTON, MA / ACCESSWIRE / July 19, 2023 / When you work for Boston Scientific-an organization dedicated to transforming lives through innovative medical solutions-your job inherently involves helping others.
Jul 13, 2023 10:50 am ET
How Boston Scientific Supports the LGBTQ+ Community All Year Long
NORTHAMPTON, MA / ACCESSWIRE / July 13, 2023 / At Boston Scientific, we stand for equality for all, and share a commitment to cultivating a corporate culture that prioritizes equality, diversity and openness.
Jun 28, 2023 09:00 am ET
Boston Scientific Announces Conference Call Discussing Second Quarter 2023 Results
MARLBOROUGH, Mass., June 28, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2023 on Thursday, July 27, 2023 at 7:30 a.m. EDT. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on July 27 prior to the conference call.
Jun 27, 2023 06:30 am ET
Boston Scientific Elects Dr. Jessica L. Mega and Susan E. Morano to Board of Directors
MARLBOROUGH, Mass., June 27, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Jessica L. Mega and Susan E. Morano to its board of directors, each effective immediately.
Jun 21, 2023 08:30 am ET
Boston Scientific's ESG Impact Is Blending Business With Sustainability
NORTHAMPTON, MA / ACCESSWIRE / June 21, 2023 / Boston Scientific
Jun 14, 2023 08:30 am ET
Boston Scientific: Giving Voice to the LGBTQ+ Community
NORTHAMPTON, MA / ACCESSWIRE / June 14, 2023 / At Boston Scientific, we encourage everyone to bring their full selves to work, knowing they'll be accepted, heard and valued.
Jun 06, 2023 08:30 am ET
Meeting the Staff Shortage Crisis With Digital Solutions
Originally published by Health Tech World online
May 30, 2023 04:30 pm ET
Boston Scientific Announces Conversion Date of Series A Mandatory Convertible Preferred Stock
MARLBOROUGH, Mass., May 30, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today that its Series A 5.50% Mandatory Convertible Preferred Stock (the preferred stock) will automatically convert into shares of the company's common stock on June 1, 2023. As previously disclosed, holders of record at the close of business on May 15, 2023 will separately receive a final quarterly cash dividend of $1.375 per share of preferred stock, payable on June 1, 2023. Following the conversion of the preferred stock, there will be no outstanding shares of preferred stock, resulting i
May 30, 2023 08:15 am ET
Six Boston Scientific Benefits That Support Employee Mental Health
NORTHAMPTON, MA / ACCESSWIRE / May 30, 2023 / Boston Scientific
May 25, 2023 08:30 am ET
"I Truly Feel I’m Able To Be Who I Am at Boston Scientific"
NORTHAMPTON, MA / ACCESSWIRE / May 25, 2023 / Boston Scientific
May 20, 2023 02:54 pm ET
Data at Heart Rhythm 2023 Highlight Key Boston Scientific Therapies
Additional real-world outcomes further demonstrate safety, efficacy and procedural reproducibility of the FARAPULSE™ Pulsed Field Ablation System*
May 15, 2023 09:00 am ET
Boston Scientific to Participate in Bernstein's 39th Annual Strategic Decisions Conference
MARLBOROUGH, Mass., May 15, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 39th Annual Strategic Decisions Conference on Wednesday, May 31, 2023.
May 09, 2023 08:40 am ET
Boston Scientific: A Sense of Belonging and Purpose
NORTHAMPTON, MA / ACCESSWIRE / May 9, 2023 / Boston Scientific
May 01, 2023 08:20 am ET
Boston Scientific Wins Two Edison Awards
NORTHAMPTON, MA / ACCESSWIRE / May 1, 2023 / Boston Scientific
Apr 26, 2023 06:30 am ET
Boston Scientific Announces Results for First Quarter 2023
MARLBOROUGH, Mass., April 26, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.389 billion during the first quarter of 2023, growing 12.0 percent on a reported basis, 14.9 percent on an operational1 basis and 14.0 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $300 million or $0.21 per share (EPS), compared to $97 million or $0.07 per share a year ago, and achieved adjusted3 EPS of $0.47 for the period, compared to $0.39 a year ago.
Apr 21, 2023 08:30 am ET
Boston Scientific Reports New Progress With Action for a Healthier, More Equitable World
NORTHAMPTON, MA / ACCESSWIRE / April 21, 2023 / Boston Scientific Corporation (NYSE:BSX) recently released its 2022 Performance Report on the company's work to innovate with medical devices and therapies to improve patient outcomes while also prioritizing environmental, social and governance (ESG) progress.
Apr 17, 2023 01:50 pm ET
5 Practical Steps for Advancing DEI in Your Medical Device Company
NORTHAMPTON, MA / ACCESSWIRE / April 17, 2023 / Boston Scientific
Apr 13, 2023 08:30 am ET
Meet Three Boston Scientific Employees Dedicated to Helping People With Parkinson's Disease
NORTHAMPTON, MA / ACCESSWIRE / April 13, 2023 / Boston Scientific employees across the globe are dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. For those who support our deep brain stimulation (DBS) products, the focus is on offering effective care options to the millions of people worldwide who are affected by Parkinson's disease (PD).
Apr 03, 2023 09:30 am ET
Boston Scientific Announces Conference Call Discussing First Quarter 2023 Results
MARLBOROUGH, Mass., April 3, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2023 on Wednesday, April 26, 2023 at 8:00 a.m. EDT. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 26 prior to the conference call.
Feb 17, 2023 10:50 pm ET
BOSTON SCIENTIFIC INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Boston Scientific Corporation - BSX
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Boston Scientific Corporation (NYSE: BSX).
Feb 13, 2023 08:30 am ET
Boston Scientific to Participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference
MARLBOROUGH, Mass., Feb. 13, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference on Wednesday, March 1, 2023.
Feb 03, 2023 09:50 pm ET
BOSTON SCIENTIFIC INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Boston Scientific Corporation - BSX
NEW ORLEANS, Feb. 3, 2023 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Boston Scientific Corporation (NYSE: BSX).
Feb 03, 2023 05:45 am ET
Boston Scientific Receives FDA Clearance for LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System
New technology designed to help inform real-time clinical decisions during kidney stone procedures
Feb 01, 2023 05:30 am ET
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022
MARLBOROUGH, Mass., Feb. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and 7.1 percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions3. The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share
Jan 23, 2023 11:54 am ET
BOSTON SCIENTIFIC INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Boston Scientific Corporation - BSX
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Boston Scientific Corporation (NYSE: BSX).
Jan 13, 2023 04:40 pm ET
APOLLO ENDOSURGERY INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apollo Endosurgery, Inc. - APEN
NEW ORLEANS, Jan. 13, 2023 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Apollo Endosurgery, Inc. (NasdaqGM: APEN) to Boston Scientific Corporation (NYSE: BSX).  Under the terms of the proposed transaction, shareholders of Apollo will receive only $10.00 in cash for each share of Apollo that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Jan 03, 2023 08:30 am ET
Boston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2022 Results
MARLBOROUGH, Mass., Jan. 3, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 in San Francisco, California. Mike Mahoney, chairman and chief executive officer, will present at approximately 8:15 a.m. PST / 11:15 a.m. EST. Mahoney will be joined by Dan Brennan, executive vice president and chief financial officer, Kenneth Stein, M.D., senior vice president and chief medical officer, Cardiac Rhythm Management, and Lauren Tengler, vice president, Investor Relations, in a question-an
Dec 11, 2022 04:17 pm ET
Boston Scientific Announces Strategic Investment to Acquire Majority Stake of Acotec Scientific Holdings Limited
MARLBOROUGH, Mass., Dec. 11, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and Acotec Scientific Holdings Limited ("Acotec" and 6669.HK) announced today that Boston Scientific will make a partial offer to acquire a majority stake, up to a maximum of 65%, of shares of Acotec, a Chinese medical technology company that offers solutions designed for a variety of interventional procedures. The proposed price is HK$20 per share, which represents a total upfront cash payment consideration of approximately US$523 million for the 65% stake at current exchange rates. 
Dec 05, 2022 12:21 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. (Nasdaq - APEN), Imago BioSciences, Inc. (Nasdaq - IMGO), Opiant Pharmaceuticals Inc.
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Nov 29, 2022 04:10 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Apollo Endosurgery, Inc.
NEW YORK, Nov. 29, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Apollo Endosurgery, Inc. ("Apollo Endosurgery" or the "Company") (NASDAQ: APEN), in connection with the proposed acquisition of the Company by Boston Scientific Corporation (NYSE: BSX). Under the terms of the merger agreement, the Company's shareholders will receive $10.00 in cash for each share of Apollo Endosurgery common stock owned. The transaction is valued at approximately $615 million.
Nov 29, 2022 06:00 am ET
Boston Scientific Announces Agreement to Acquire Apollo Endosurgery, Inc.
Acquisition to expand endoluminal surgery portfolio and add differentiated technologies for endobariatric procedures
Nov 27, 2022 11:04 am ET
Late-Breaking Post-Market Study Data Reinforce Clinical Procedural Success and Safety of the ACURATE neo2™ Aortic Valve System
MARLBOROUGH, Mass., Nov. 27, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has announced the first results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) study evaluating the performance of the ACURATE neo2TM Aortic Valve System. The findings, which included a high procedural success rate of 98.4% and low rates of mortality and paravalvular leak (PVL), were presented during a late-breaking clinical trial session at PCR London Valves 2022 and published simultaneously in EuroIntervention.
Nov 11, 2022 09:00 am ET
Boston Scientific's Commitment to Diversity Is Recognized by Seramount
NORTHAMPTON, MA / ACCESSWIRE / November 11, 2022 / Our commitment to advancing diversity, equity and inclusion in the workplace has been recognized by Seramount, part of EAB's 2022 Inclusion Index! Read more about our best practices: https://bit.ly/3G2szZh
Nov 01, 2022 09:30 am ET
Boston Scientific Announces Upcoming Conference Schedule
MARLBOROUGH, Mass., Nov. 1, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.
Oct 26, 2022 12:20 pm ET
12 Employee Benefits That Make Boston Scientific a "Best Place To Work"
NORTHAMPTON, MA / ACCESSWIRE / October 26, 2022 / Boston Scientific
Oct 26, 2022 06:30 am ET
Boston Scientific Announces Results for Third Quarter 2022
MARLBOROUGH, Mass., Oct. 26, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.170 billion during the third quarter of 2022, growing 8.1 percent on a reported basis, 13.7 percent on an operational1 basis and 11.5 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income available to common stockholders of $174 million or $0.12 per share (EPS), compared to $405 million or $0.28 per share a year ago, and achieved adjusted3 EPS of $0.43 for the period, compared to $0.41 a year ago.
Oct 03, 2022 09:30 am ET
Boston Scientific Announces Conference Call Discussing Third Quarter 2022 Results
MARLBOROUGH, Mass., Oct. 3, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2022 on Wednesday, October 26, 2022 at 8:00 a.m. EDT. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter on October 26 prior to the conference call.
Sep 30, 2022 10:45 am ET
Thinking about buying stock in Microsoft, Royal Caribbean Cruises, Meta, Boston Scientific, or Dick's Sporting Goods?
NEW YORK, Sept. 30, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MSFT, RCL, META, BSX, and DKS.
Sep 06, 2022 06:55 am ET
Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX™ LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option
WATCHMAN FLX now the only LAAC technology in the United States that allows for either DAPT or OAC immediately following implantation
Aug 16, 2022 02:00 pm ET
Boston Scientific Announces Upcoming Conference Schedule
MARLBOROUGH, Mass., Aug. 16, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor events.
Aug 15, 2022 07:00 am ET
Boston Scientific Announces Acquisition of Obsidio, Inc.
Company to add novel technology cleared for use in peripheral vasculature to interventional oncology and embolization portfolio
Aug 01, 2022 07:00 am ET
Nevro and Boston Scientific Announce the Settlement of Their Ongoing Intellectual Property Litigations
Parties Reach an Agreement that Concludes Outstanding Intellectual Property Disputes
Jul 27, 2022 06:30 am ET
Boston Scientific Announces Results for Second Quarter 2022
MARLBOROUGH, Mass., July 27, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.244 billion during the second quarter of 2022, growing 5.4 percent on a reported basis, 9.6 percent on an operational1 basis and 6.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income available to common stockholders of $246 million or $0.17 per share (EPS), compared to $172 million or $0.12 per share a year ago, and achieved adjusted3 EPS of $0.44 for the period, compared to $0.40 a year ago.
Jun 29, 2022 09:30 am ET
Boston Scientific Announces Conference Call Discussing Second Quarter 2022 Results
MARLBOROUGH, Mass., June 29, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2022 on Wednesday, July 27, 2022 at 8:00 a.m. EDT. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on July 27 prior to the conference call.
Jun 15, 2022 07:00 am ET
Boston Scientific Announces Agreement to Purchase Majority Stake of M.I.Tech Co., Ltd from Synergy Innovation Co., Ltd
MARLBOROUGH, Mass., June 15, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Synergy Innovation Co., Ltd, to purchase its majority stake (approximately 64 percent) of M.I.Tech Co., Ltd, ("M.I.Tech") a publicly traded Korean manufacturer and distributor of medical devices for endoscopic and urologic procedures. M.I.Tech is the creator of the HANAROSTENT™ technology, a family of conformable, non-vascular, self-expanding metal stents, which have been distributed by Boston Scientific in Japan since 2015. The agre
May 02, 2022 09:30 am ET
Boston Scientific to Participate in Bank of America Global Healthcare Conference
MARLBOROUGH, Mass., May 2, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bank of America's Global Healthcare Conference on Thursday, May 12.
Apr 27, 2022 06:30 am ET
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2022
MARLBOROUGH, Mass., April 27, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational1 basis and 9.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income available to common stockholders of $97 million or $0.07 per share (EPS), compared to $327 million or $0.23 per share a year ago, and achieved adjusted EPS of $0.39 for the period, compared to $0.37 a year ago.
Apr 01, 2022 09:00 am ET
Boston Scientific Announces Conference Call Discussing First Quarter 2022 Results
MARLBOROUGH, Mass., April 1, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2022, on Wednesday, April 27, 2022, at 8:00 a.m. EDT. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 27 prior to the conference call.
Mar 16, 2022 04:58 pm ET
Boston Scientific Announces Pricing Terms of Its Cash Tender Offer
MARLBOROUGH, Mass., March 16, 2022 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced the pricing terms of the previously announced upsized cash tender offer (the "Tender Offer") for $2,852,561,000 in aggregate principal amount (the "Aggregate Maximum Principal Amount") of the outstanding senior notes identified in the table and the related notes below (the "Securities").
Mar 16, 2022 06:30 am ET
Boston Scientific Announces Early Results of Its Cash Tender Offer for Its Outstanding Debt Securities and Increases Aggregate Maximum Principal Amount of Its Cash Tender Offer
MARLBOROUGH, Mass., March 16, 2022 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $2.5 billion aggregate principal amount of the outstanding senior notes identified in the table and the related notes below (the "Securities"), $5,139,194,000 in aggregate principal amount of the Securities were validly tendered and not validly withdrawn on or prior to 5:00 p.m., Eastern Time, on March 15, 2022 (the "Early Tender Date"). The Company also announced that it has ame
Mar 08, 2022 03:30 pm ET
Boston Scientific Announces Completion of €3.0 Billion Offering of Senior Notes
MARLBOROUGH, Mass., March 8, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) (the "Company") today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has completed a public offering of €1,000,000,000 aggregate principal amount of 0.750% notes due 2025, €750,000,000 aggregate principal amount of 1.375% notes due 2028, €750,000,000 aggregate principal amount of 1.625% notes due 2031 and €500,000,000 aggregate principal amount of 1.875% notes due 2034 (collectively, the "Notes"). The Notes are fully and unconditionally guaranteed by the Comp
Mar 04, 2022 05:25 am ET
Boston Scientific Announces Pricing of €3.0 Billion of Senior Notes
MARLBOROUGH, Mass., March 4, 2022 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has priced a public offering of €1,000,000,000 aggregate principal amount of 0.750% notes due 2025, €750,000,000 aggregate principal amount of 1.375% notes due 2028, €750,000,000 aggregate principal amount of 1.625% notes due 2031 and €500,000,000 aggregate principal amount of 1.875% notes due 2034 (collectively, the "Notes"). The Notes will be fully and unconditionally guaranteed by the Com
Mar 02, 2022 03:49 am ET
Boston Scientific Announces Cash Tender Offer for up to $2.5 Billion of Its Outstanding Debt Securities
MARLBOROUGH, Mass., March 2, 2022 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced the commencement of a cash tender offer (the "Tender Offer") for up to $2.5 billion aggregate principal amount (the "Aggregate Maximum Principal Amount") of the outstanding senior notes listed in the table below (the "Securities").
Feb 28, 2022 11:03 am ET
Late-Breaking Study Results Reinforce Positive Real-World Outcomes with the WATCHMAN FLX™ LAAC Device
MARLBOROUGH, Mass., Feb. 28, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive results from a new analysis assessing real-world outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Presented during a late-breaking trial session at the Cardiovascular Research Technologies (CRT) 2022 meeting, the SURPASS analysis included data from more than 16,000 patients with non-valvular atrial fibrillation within the National Cardiovascular Data Registry (NCDR) Left Atrial Appendage Occlusion (LAAO) Registry.
Feb 15, 2022 06:00 am ET
Boston Scientific Closes Acquisition of Baylis Medical Company Inc.
MARLBOROUGH, Mass., Feb. 15, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures.
Feb 14, 2022 08:30 am ET
Boston Scientific to Participate in 11th Annual SVB Leerink Global Healthcare Conference
MARLBOROUGH, Mass., Feb. 14, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in SVB Leerink's 11th Annual Global Healthcare Conference on Thursday, February 17, 2022.
Feb 02, 2022 09:50 am ET
Thinking about buying stock in OLB Group, SoFi Technologies, Boston Scientific, Dynatrace, or Exelon Corp?
NEW YORK, Feb. 2, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OLB, SOFI, BSX, DT, and EXC.
Feb 02, 2022 05:30 am ET
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2021
MARLBOROUGH, Mass., Feb. 2, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.127 billion during the fourth quarter of 2021, growing 15.4 percent on a reported basis, 16.9 percent on an operational1 basis and 15.1 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income available to common stockholders of $80 million or $0.06 per share (EPS), compared to $196 million or $0.14 per share a year ago and achieved adjusted EPS of $0.45 for the period, compared to $0.23 a year ago.
Jan 13, 2022 08:31 am ET
Thinking about trading options or stock in JinkoSolar, Taiwan Semiconductor, Freeport-McMoRan, Boston Scientific, or Tesla?
NEW YORK, Jan. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JKS, TSM, FCX, BSX, and TSLA.
Jan 07, 2022 06:00 am ET
Boston Scientific to Present New Data on Advances in Chronic Pain Care at the 2022 North American Neuromodulation Society (NANS) Meeting
MARLBOROUGH, Mass., Jan. 7, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at the 25th North American Neuromodulation Society (NANS) annual meeting, in Orlando, Florida, on Jan.13-15, 2022. More than 20 abstracts have been accepted, including three late-breaking presentations.
Jan 04, 2022 08:04 am ET
Boston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2021 Results
MARLBOROUGH, Mass., Jan. 4, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022. Mike Mahoney, chairman and chief executive officer, will present at ­­­8:15 a.m. EST. Mahoney will be joined by Dan Brennan, executive vice president and chief financial officer, and Lauren Tengler, vice president, Investor Relations, in a question-and-answer session with the host analyst.
Dec 02, 2021 06:00 am ET
Boston Scientific Initiates Trial to Evaluate Industry's First Modular CRM System
MARLBOROUGH, Mass., Dec. 2, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™ Modular Therapy System. The mCRM System consists of two cardiac rhythm management (CRM) devices intended to work together to coordinate therapy: the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Modular Pacing System (MPS), which is designed to be the first leadless pacemaker capable of delivering both bradycardia pacing support and antitachycardia pacing
Nov 08, 2021 08:30 am ET
Boston Scientific Announces Upcoming Conference Schedule
MARLBOROUGH, Mass., Nov. 8, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.
Oct 27, 2021 09:31 am ET
Thinking about buying stock in Edwards Lifesciences, General Motors, Pinterest, Boston Scientific, or General Electric?
NEW YORK, Oct. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EW, GM, PINS, BSX, and GE.
Oct 27, 2021 06:30 am ET
Boston Scientific Announces Results For Third Quarter 2021
MARLBOROUGH, Mass., Oct. 27, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported basis, 9.7 percent on an operational1 basis and 10.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income available to common stockholders of $405 million or $0.28 per share (EPS), compared to a GAAP net loss available to common shareholders of $169 million or $(0.12) per share a year ago, and achieved adjusted EPS of $0.41 for the period, c
Oct 06, 2021 12:35 pm ET
Boston Scientific Eluvia™ Drug-Eluting Vascular Stent System Exhibits Superiority Compared to Bare Metal Stents
LAS VEGAS and MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ -- Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas. Data presented included one-year results from the EMINENT trial, which demonstrated superiority of the Eluvia stent compared to self-expanding bare metal stents (BMS) for the treatment of patients with peripheral artery disease (PAD) and superficial femoral artery (SFA) or po
Oct 06, 2021 07:00 am ET
Boston Scientific Announces Agreement to Acquire Baylis Medical Company Inc.
MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to closing adjustments. The acquisition will expand the Boston Scientific electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG® and VersaCross® Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access. These platforms have advanced transseptal puncture and
Oct 05, 2021 04:21 pm ET
Positive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21
LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas. Data from the KNOCOUT PE registry – established to measure institutional adoption of a lower dose and lower-duration thrombolysis protocol for the EKOS system – confirmed the safety and efficacy of the EKOS system for the treatment of patients with intermediate-high and high-risk pulmonary embolism
Oct 05, 2021 12:35 pm ET
Boston Scientific Announces Positive Late-Breaking Clinical Trial Data for the Ranger™ Drug-Coated Balloon
LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas. The data included two- year results from the RANGER II SFA randomized controlled trial, confirming the safety and efficacy of the Ranger DCB compared to standard percutaneous transluminal angioplasty (PTA) for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (S
Oct 04, 2021 10:30 am ET
Boston Scientific Announces Conference Call Discussing Third Quarter 2021 Results
MARLBOROUGH, Mass., Oct. 4, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2021 on Wednesday, October 27, 2021 at 8:00 a.m. EDT. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter on October 27 prior to the conference call.
Sep 21, 2021 07:00 am ET
Boston Scientific Announces Agreement to Acquire Devoro Medical, Inc.
MARLBOROUGH, Mass., Sept. 21, 2021 /PRNewswire/ -- Today, Boston Scientific Corporation (NYSE: BSX) announced an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy® Platform. The innovative non-console and lytic-free WOLF technology targets and rapidly captures blood clots using finger-like prongs that retrieve and remove thrombi in the arterial and venous systems.
Sep 20, 2021 07:36 am ET
Late-Breaking Data Demonstrate Improved Progression-Free Survival in Patients with Metastatic Colorectal Cancer After Treatment with Boston Scientific TheraSphere™ Y-90 Glass Microspheres
MARLBOROUGH, Mass., Sept. 20, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced the EPOCH clinical trial of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere treatment) successfully met both primary endpoints, including progression-free survival (PFS) and hepatic progression-free survival (hPFS) of patients with metastatic colorectal cancer (mCRC) of the liver. In the trial, TheraSphere treatment – a selective internal radiation therapy (SIRT) comprised of microscopic glass beads containing radioactive yttrium (Y-90) that are specifically delivered to target tumors
Sep 09, 2021 10:45 am ET
Boston Scientific Announces 2021 Investor Day Meeting
MARLBOROUGH, Mass., Sept. 9, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 22, 2021, from 8:30 a.m. – 12:30 p.m. EDT. Company leaders will also provide business unit market overviews, pipeline updates and spotlight key products from the company's Cardiovascular, MedSurg and Rhythm and Neuro segments.
Sep 01, 2021 06:50 am ET
Boston Scientific Closes Acquisition Of Lumenis LTD. Surgical Business From Baring Private Equity Asia
MARLBOROUGH, Mass., Sept. 1, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced the close of its acquisition of the global surgical business of Lumenis LTD., a privately-held company that develops and commercializes energy-based medical solutions, from an affiliate of Baring Private Equity Asia (BPEA). The Lumenis surgical business includes premier laser systems, fibers and accessories used for urology and otolaryngology procedures with total revenue anticipated to be approximately $200 million for full year 2021.
Aug 10, 2021 04:00 pm ET
Boston Scientific Receives FDA Clearance for EXALT™ Model B Single-Use Bronchoscope
MARLBOROUGH, Mass., Aug. 10, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model B Single-Use Bronchoscope, designed for use in bedside procedures within the intensive care unit (ICU) and operating room (OR).
Aug 04, 2021 07:00 am ET
Boston Scientific Initiates Randomized Controlled Trial for the EkoSonic™ Endovascular System
MARLBOROUGH, Mass., Aug. 4, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and the University Medical Center of the Johannes Gutenberg University of Mainz comparing use of the EkoSonic™ Endovascular System (EKOS) in combination with anticoagulation to anticoagulation alone for the treatment of acute, intermediate-high-risk pulmonary embolism (PE).
Aug 02, 2021 04:55 pm ET
CMS Grants Additional Reimbursement For EXALT™ Model D Single-Use Duodenoscope
MARLBOROUGH, Mass., Aug. 2, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for single-use duodenoscopes, applicable to the EXALT™ Model D Single-Use Duodenoscope, as part of its Fiscal Year 2022 Hospital Inpatient Prospective Payment System. NTAP was created to facilitate patient access for qualifying new medical technologies that substantially improve the diagnosis or treatment of Medicare beneficiaries. Beginning October 1, 2021, CMS will provide hospitals with addi
Jul 27, 2021 06:30 am ET
Boston Scientific Announces Results For Second Quarter 2021
MARLBOROUGH, Mass., July 27, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.077 billion during the second quarter of 2021, growing 53.6 percent on a reported basis, 49.6 percent on an operational1 basis and 52.4 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income available to common stockholders of $172 million or $0.12 per share (EPS), compared to a GAAP net loss available to common shareholders of $153 million or $(0.11) per share a year ago, and achieved adjusted EPS of $0.40 for the period,
Jul 21, 2021 07:13 am ET
Late-Breaking Trial Data at TVT Demonstrate Sustained Safety and Performance of WATCHMAN FLX™ Left Atrial Appendage Closure Device
MARLBOROUGH, Mass., July 21, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device for patients with non-valvular atrial fibrillation (NVAF). Presented as late-breaking clinical science at TVT: The Structural Heart Summit, the study evaluated the WATCHMAN FLX device as an alternative to long-term oral anticoagulation therapy, including non-vitamin K antagonist oral anticoagulants (NOACs), for stroke ris
Jun 29, 2021 09:30 am ET
Boston Scientific Announces Conference Call Discussing Second Quarter 2021 Results
MARLBOROUGH, Mass., June 29, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2021 on Tuesday, July 27, 2021 at 8:00 a.m. EDT. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on July 27 prior to the conference call.
Jun 24, 2021 04:50 pm ET
Boston Scientific Elects David S. Wichmann To Board Of Directors
MARLBOROUGH, Mass., June 24, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of David S. Wichmann to its board of directors, effective immediately.
Jun 24, 2021 07:00 am ET
Boston Scientific Exercises Option to Acquire Farapulse, Inc.
MARLBOROUGH, Mass., June 24, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition will complement the existing Boston Scientific electrophysiology portfolio to include the FARAPULSE Pulsed Field Ablation (PFA) System – a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias.  
May 25, 2021 06:54 am ET
Boston Scientific Completes CE Mark for EXALT™ Model B Single-Use Bronchoscope
Company to begin limited market release in Europe in June
May 14, 2021 10:50 pm ET
BOSTON SCIENTIFIC INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Boston Scientific Corporation - BSX
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Boston Scientific Corporation (NYSE: BSX).
Apr 16, 2021 10:50 pm ET
BOSTON SCIENTIFIC INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Boston Scientific Corporation - BSX
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Boston Scientific Corporation (NYSE: BSX).
Feb 12, 2021 08:30 am ET
Boston Scientific Announces February and March 2021 Conference Schedule
MARLBOROUGH, Mass., Feb. 12, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.
Feb 11, 2021 07:30 am ET
Global Cardiovascular Devices Market Now Project to Exceed $71 Billion By 2027
Palm Beach, Fl., Feb. 11, 2021 /PRNewswire/ -- Cardiovascular devices are the medical devices which are used to diagnosis and treat the heart diseases and other heart-related problems.  These devices play essential role prevention and treatment of cardiovascular diseases. The cardiovascular devices include implantable cardioverter defibrillators, implanted heart rhythm monitors, pacemakers, and various other devices. The cardiovascular devices market is currently witnessing considerable demand across the globe. Increasing awareness about the various cardiovascular diseases and increasing ger
Feb 03, 2021 05:30 am ET
Boston Scientific Announces Results For Fourth Quarter And Full Year 2020
MARLBOROUGH, Mass., Feb. 3, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) percent on a reported basis, (8.3) percent on an operational1 basis and (8.0) percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative 370 basis point impact associated with the conversion of U.S. WATCHMAN™ customers to a consignment inventory model and transition to the next-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) De
Feb 02, 2021 09:11 am ET
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Boston Scientific Corporation and Encourages Investors with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or “the Company”) (NYSE:
Feb 02, 2021 12:50 am ET
BOSTON SCIENTIFIC 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Bo
NEW ORLEANS, Feb. 2, 2021 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until February 2, 2021 to file lead plaintiff applications in a securities class action lawsuit against Boston Scientific Corporation (NYSE: BSX), if they purchased the Company's securities between April 24, 2019 and November 16, 2020, inclusive (the "Class Period").  This action is pending in the United States District Court for the Eastern District of New York.
Feb 01, 2021 11:00 am ET
BSX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Boston Scientific Corporation Shareholders of Class Action and Lead Plaintiff Deadline: February 3, 2021
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NASDAQ: BSX) and certain of its officers, on...
Feb 01, 2021 10:49 am ET
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Boston Scientific Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Fi
LOS ANGELES, Feb. 1, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Boston Scientific Corporation ("Boston Scientific" or "the Company") (NYSE: BSX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Feb 01, 2021 09:41 am ET
BSX FINAL DEADLINE TOMORROW: ROSEN, TOP RANKED INVESTOR COUNSEL, Reminds Boston Scientific Corporation Investors of Important February 2 Deadline in Securities Class Action – BSX
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021...
Feb 01, 2021 08:43 am ET
BSX FILING DEADLINE TOMORROW: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Lawsuit Against Boston Scientific Corporation
NEW YORK, Feb. 1, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) from April 24, 2019 through November 16, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the Eastern District of New York alleges violations of the Securities Exchange Act of 1934.
Jan 31, 2021 04:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadline - BSX
NEW YORK, Jan. 31, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and certain of its officers.  The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05894, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Boston Scientific securities between April 24, 2019 and November 16, 2020, both dates inclusive (the "Class Period"), seeking to recover
Jan 31, 2021 04:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadline - BSX
NEW YORK, Jan. 31, 2021 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and certain of its officers.  The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05894, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Boston Scientific securities between April 24, 2019 and November 16, 2020, both dates inclusive (the "Class Period"), seeking to recover damages
Jan 30, 2021 11:21 pm ET
BSX FILING DEADLINE IN 4 DAYS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Lawsuit Against Boston Scientific Corporation
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Jan 29, 2021 10:50 pm ET
BOSTON SCIENTIFIC 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Bo
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until February 2, 2021 to file lead plaintiff applications in a securities class action lawsuit against Boston Scientific Corporation (NYSE: BSX), if they purchased the Company’s securities between April 24, 2019 and November 16, 2020, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of New York.
Jan 29, 2021 09:00 am ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Boston Scientific Corporation (BSX)
The Law Offices of Frank R. Cruz reminds investors of the upcoming February 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE:
Jan 28, 2021 12:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Boston Scientific Corporation (BSX)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Boston Scientific Corporation...
Jan 28, 2021 08:00 am ET
Boston Scientific Corporation Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Boston Scientific Corporation (NYSE: BSX) investors that acquired shares between April 24, 2019 and November 16, 2020. Investors have until February 3,...
Jan 27, 2021 11:04 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BSX, SPLK INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Boston Scientific Corporation (BSX) Class...
Jan 27, 2021 06:17 pm ET
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors with Losses in Excess of $50,000 to Contact the Firm
SAN DIEGO, Jan. 27, 2021 /PRNewswire/ -- Johnson Fistel, LLP, announces that class action lawsuits have commenced on behalf of shareholders of the publicly-traded companies listed below. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation.  The lead plaintiff can select a law firm of its choice.  An investor's ability to share in any potential future recovery is not dependent upon serving as lead
Jan 26, 2021 10:40 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BSX and SPLK
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Boston Scientific Corporation (BSX) Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Motion...
Jan 26, 2021 11:00 am ET
BSX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Boston Scientific Corporation Shareholders of Class Action and Lead Plaintiff Deadline: February 3, 2021
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NASDAQ: BSX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Boston Scientific securities between April 24, 2019 to November 16, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Jan 26, 2021 11:00 am ET
DEADLINE ALERT for SPLK, BSX, QIWI and PEN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 25, 2021 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BSX, SPLK INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Boston Scientific Corporation (BSX) Class Period: 4/24/2019 - 11/16/2020Lead Plaintiff Motion Deadline:...
Jan 25, 2021 07:11 pm ET
Kaplan Fox Has Filed a Class Action to Recover Losses for Investors Who Purchased Boston Scientific Corporation Securities
NEW YORK, Jan. 25, 2021 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has filed a class action suit in the United States District Court for the District of Massachusetts against Boston Scientific Corporation ("Boston Scientific" or "BSX" or the "Company") (NYSE: BSX) and certain of its executives.
Jan 25, 2021 12:06 pm ET
ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Boston Scientific Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses Exceeding $100K to Contact Firm – BS
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021...
Jan 25, 2021 11:30 am ET
DEADLINE ALERT for FBIO, SPLK, and BSX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 22, 2021 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BSX, SPLK INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Boston Scientific Corporation (BSX) Class...
Jan 22, 2021 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Boston Scientific Corporation (BSX)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Boston Scientific Corporation...
Jan 22, 2021 06:00 am ET
Boston Scientific Receives FDA Approval For The Vercise Genus™ Deep Brain Stimulation System
MARLBOROUGH, Mass., Jan. 22, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval of its fourth-generation Vercise Genus™ Deep Brain Stimulation (DBS) System. The portfolio, approved for conditional use in a magnetic resonance imaging (MRI) environment,i consists of a family of Bluetooth-enabled, rechargeable and non-rechargeable, implantable pulse generators (IPGs) that power Cartesia™ Directional Leads, designed to provide optimal symptom relief. 
Jan 21, 2021 05:53 pm ET
ROSEN, LEADING INVESTOR COUNSEL, Reminds Boston Scientific Corporation Investors of Important February 2 Deadline in Securities Class Action; Encourages Investors with Losses Exceeding $100K to Contac
NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Boston Scientific investors under the federal securities laws.
Jan 21, 2021 11:00 am ET
BSX, NERV & SMICY Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Shareholders to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jan 21, 2021 11:00 am ET
DEADLINE ALERT for FBIO, SPLK, and BSX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 21, 2021 05:55 am ET
Boston Scientific Announces Agreement To Acquire Preventice Solutions, Inc.
MARLBOROUGH, Mass., Jan. 21, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Preventice Solutions, Inc., a privately-held company which offers a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors – including short and long-term Holter monitors – to cardiac event monitors and mobile cardiac telemetry. The transaction consists of an upfront cash payment of $925 million, and up to an additional $300 million in a potential commercial milestone payment. Boston Scient
Jan 20, 2021 07:22 pm ET
Portnoy Law: Lawsuit Filed On Behalf of Boston Scientific Corporation Investors
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Boston Scientific Corporation ("Boston Scientific" or "the Company") (NYSE: BSX) investors that acquired securities between April 24, 2019 and November...
Jan 20, 2021 11:00 am ET
DEADLINE ALERT for FBIO, SPLK, BSX, and QIWI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 20, 2021 10:00 am ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Boston Scientific Corporation (BSX) Investors
LOS ANGELES, Jan. 20, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) securities between April 24, 2019  and November 16, 2020 inclusive (the "Class Period"). Boston Scientific investors have until February 2, 2021 to file a lead plaintiff motion.
Jan 19, 2021 10:26 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BSX and SPLK
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Boston Scientific Corporation (BSX) Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Motion...
Jan 18, 2021 10:46 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BSX, QS, SPLK, SWI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Boston Scientific Corporation (BSX) Class...
Jan 15, 2021 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BSX, QS, SPLK, SWI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Boston Scientific Corporation (BSX)Class Period: 4/24/2019 - 11/16/2020Lead Plaintiff Motion Deadline:...
Jan 15, 2021 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Boston Scientific Corporation (BSX)
LOS ANGELES, Jan. 15, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming February 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) securities between April 24, 2019 and November 16, 2020, inclusive (the "Class Period").
Jan 14, 2021 06:00 am ET
Boston Scientific Launches WaveWriter Alpha™ Spinal Cord Stimulator Systems In U.S.
MARLBOROUGH, Mass., Jan. 14, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX) has announced a limited market release of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) systems. The unified portfolio of four MRI conditional, Bluetooth-enabled rechargeable and non-rechargeable implantable pulse generators (IPGs) provides uncompromised personalization, and for the first time in SCS, Fast Acting Sub-perception Therapy (FAST™) designed to deliver profound paresthesia-free pain relief in minutes.i The systems are supported by the Cognita™ Solutions suite of digital tools for pati
Jan 13, 2021 10:26 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BSX, QS, SPLK, SWI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Boston Scientific Corporation (BSX) Class Period:...
Jan 13, 2021 05:30 pm ET
ROSEN, A TOP RANKED LAW FIRM, Reminds Boston Scientific Corporation Investors of Important February 2 Deadline in Securities Class Action; Encourages Investors with Losses Exceeding $100K to Contact F
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021...
Jan 13, 2021 10:00 am ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Boston Scientific Corporation (BSX)
BENSALEM, Pa., Jan. 13, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming February 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) securities between April 24, 2019 and November 16, 2020 inclusive (the "Class Period").
Jan 12, 2021 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BSX, QS, SPLK and SWI
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Boston Scientific Corporation (BSX) Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Motion...
Jan 12, 2021 11:00 am ET
DEADLINE ALERT for SPLK and BSX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 12, 2021 05:30 am ET
Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year 2020
MARLBOROUGH, Mass., Jan. 12, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE:  BSX) generated net sales, based upon preliminary unaudited financial information, of approximately $2.71 billion during the fourth quarter of 2020. This represents a decline of approximately (6.8) percent on a reported basis, approximately (8.3) percent on an operational1 basis and approximately (8.0) percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative 370 basis point impact associated with the conversion of U.S. WATCHMAN™ customers to a consi
Jan 11, 2021 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BSX, QS, SPLK, SWI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Boston Scientific Corporation (BSX) Class Period: 4/24/2019 - 11/16/2020Lead Plaintiff Motion Deadline:...
Jan 11, 2021 12:30 pm ET
DEADLINE ALERT for FBIO, SPLK, BSX, and QIWI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 08, 2021 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BSX, SPLK, SWI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Boston Scientific Corporation (BSX)Class Period:...
Jan 08, 2021 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Boston Scientific Corporation (BSX)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Boston Scientific Corporation...
Jan 06, 2021 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BSX, SPLK INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Boston Scientific Corporation (BSX) Class Period: 4/24/2019 - 11/16/2020Lead Plaintiff Motion Deadline:...
Jan 06, 2021 03:57 pm ET
Kaplan Fox Has Filed a Class Action to Recover Losses for Investors Who Purchased Boston Scientific Corporation Securities
NEW YORK, Jan. 6, 2021 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has filed a class action suit in the United States District Court for the District of Massachusetts against Boston Scientific Corporation ("Boston Scientific" or "BSX" or the "Company") (NYSE: BSX) and certain of its executives.
Jan 06, 2021 03:31 pm ET
ROSEN, A TOP RANKED LAW FIRM, Reminds Boston Scientific Corporation Investors of Important February 2 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contac
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021...
Jan 06, 2021 11:00 am ET
DEADLINE ALERT for SPLK and BSX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 06, 2021 08:23 am ET
UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Boston Scientific Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact
LOS ANGELES, Jan. 6, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Boston Scientific Corporation ("Boston Scientific" or "the Company") (NYSE: BSX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jan 05, 2021 10:30 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BSX and SPLK
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Boston Scientific Corporation (BSX)Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Motion...
Jan 04, 2021 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BSX, SPLK INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Boston Scientific Corporation (BSX)Class Period:...
Jan 04, 2021 11:36 am ET
DEADLINE ALERT for FBIO, SPLK, BSX, and QIWI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 04, 2021 08:30 am ET
Boston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2020 Results
MARLBOROUGH, Mass., Jan. 4, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the virtually held 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Mike Mahoney, chairman and chief executive officer, will present at 8:20 a.m. EST. At approximately 8:40 a.m. EST, Mahoney will be joined by Dan Brennan, executive vice president and chief financial officer, Dr. Ian Meredith, AM, executive vice president and global chief medical officer, and Susie Lisa, vice president, Investor Relations, in a question-and-answer session with the host anal
Jan 03, 2021 02:12 am ET
SHAREHOLDER ALERT; Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadline - BSX
NEW YORK, Jan. 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05894, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Boston Scientific securities between April 24, 2019 and November 16, 2020, both dates inclusive (the "Class Period"), seeking to recover da
Jan 01, 2021 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BSX, SPLK INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Boston Scientific Corporation (BSX) Class Period: 4/24/2019 - 11/16/2020Lead Plaintiff Motion Deadline:...
Dec 31, 2020 12:53 pm ET
BSX SHAREHOLDER DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Lawsuit Against Boston Scientific Corporation
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Dec 30, 2020 10:27 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BSX, SPLK INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Boston Scientific Corporation (BSX) Class Period:...
Dec 29, 2020 10:16 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BSX and SPLK
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Boston Scientific Corporation (BSX) Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Motion...
Dec 29, 2020 03:29 pm ET
ROSEN, RESPECTED INVESTOR COUNSEL Reminds Boston Scientific Corporation Investors of the Important February 2 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K t
NEW YORK, Dec. 29, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Boston Scientific investors under the federal securities laws.
Dec 29, 2020 11:02 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Boston Scientific Corporation (BSX)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Boston Scientific Corporation...
Dec 29, 2020 11:00 am ET
BSX, NERV & SMICY Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Dec 28, 2020 10:44 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BSX, SPLK INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Boston Scientific Corporation (BSX) Class Period: 4/24/2019 - 11/16/2020Lead Plaintiff Motion Deadline:...
Dec 28, 2020 11:30 am ET
DEADLINE ALERT for SPLK and BSX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 25, 2020 10:54 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BSX, SPLK INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Boston Scientific Corporation (BSX) Class Period:...
Dec 23, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BSX, RTX, SPLK INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Raytheon Technologies Corporation f/k/a Raytheon Company (RTX, RTN) Class Period: 2/10/2016 -...
Dec 22, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BSX, RTX and SPLK
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Raytheon Technologies Corporation f/k/a Raytheon Company (RTX, RTN)Class Period: February 10, 2016 and October...
Dec 22, 2020 02:30 pm ET
LEADING ROSEN LAW FIRM Reminds Boston Scientific Corporation Investors of the Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – B
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 to November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead...
Dec 21, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BSX, RTX, SPLK INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Raytheon Technologies Corporation f/k/a Raytheon...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.